For the combined analysis of BRCA1 and BRCA2 PV carriers, Grann et al. [44] found that RRM at the age of 30 was cost-effective, with an ICER ranging from $571/LYG to $2539/LY, and that RRSO or combined RRM and RRSO at the age of 30 was cost-saving, for the 40–85% BC-risk and 6–63% OC-risk used in their model. This evidence concerns the gene BRCA2 and breast cancer.